NEW YORK (GenomeWeb News) – WaferGen BioSystems said this week that its revenues for the second quarter rose 12-fold year over year.

The Fremont, Calif.-based company reported total revenues of $246,248 for the three months ended June 30, up from $20,158 a year ago. The uptick resulted from $125,000 in license and royalty revenues in the recently completed quarter, compared to none a year ago. Product revenues increased to $121,248 from $20,158 in the second quarter of 2012.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

A research duo estimates in PLOS One the number of papers that have used misidentified cell lines.

UK's National Institute for Health and Care Excellence approves GlaxoSmithKline's SCID gene therapy despite cost.

Science reports that Brazilian researchers are petitioning for the reversal of budget cuts.

In PLOS this week: gene flow patterns in common ash, guidelines for using morpholinos in zebrafish, and more.